Ovarian cancer

Nicoletta Colombo(University of Milano-Bicocca), Ignace Vergote(KU Leuven), Gemma Gatta(Fondazione IRCCS Istituto Nazionale dei Tumori), Cristiana Sessa(Institute of Oncology Research), Gabriella Parma(European Institute of Oncology), Toon Van Gorp, Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)

Critical Reviews in Oncology/Hematology

October 3, 2006

10.1016/j.critrevonc.2006.03.004

Cited by 218

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

|New England Journal of Medicine|2016|2.5k

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

|Annals of Oncology|2015|1.4k

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

|Annals of Oncology|2019|1.2k

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2013|1.1k

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

|Journal of Clinical Oncology|2000|840